Last reviewed · How we verify

NCT05809674

Polarization Sensitive Optical Coherence Tomography

Completed Last updated 12 April 2023
What this trial tests

trial testing Polarization sensitive optical coherence tomography (PS-OCT) in Myopia in 178 participants. Completed in 31 March 2023.

Timeline
10 March 2022
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorSingapore Eye Research Institute
StatusCompleted
Study typeOBSERVATIONAL
Enrollment178
Start date10 March 2022
Primary completion31 March 2023
Estimated completion31 March 2023
Sites1 location across Singapore

Drugs / interventions tested

Conditions studied

Sponsor

Singapore Eye Research Institute

Who can join

Adults 10 to 99, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to use the polarization sensitive optical coherence tomography (PS-OCT) developed by Singapore Eye Research Institute, to evaluate the potential OCT scleral biomarkers capable of predicting risk of myopia progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Singapore Eye Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing